Silence Therapeutics plc entered into a definitive agreement with Merck KGaA, Darmstadt, Germany, to be acquired in an all-cash transaction valued at approximately $1.3 billion in equity value and $1.1 billion in enterprise value. Under the terms of the scheme of arrangement, shareholders will receive $20.00 per American Depositary Share (ADS), representing a 130% premium to the closing price on October 16, 2026. The transaction requires approval by Silence shareholders, sanction by the High Court of Justice in England and Wales, and customary regulatory clearances, including Hart-Scott-Rodino review. Closing is expected in the first quarter of 2027. Silence Therapeutics plc is a clinical-stage biotechnology company developing precision engineered medicines using proprietary siRNA technology.
